Screener
Kymera Therapeutics KYMR Q3 2026 earnings
Reported October 29, 2026 · Before market open
Revenue$1.4MMiss by $1.9M
EPS-$1.32Miss by $0.06
Revenue estimate$3.3M
EPS estimate-$1.26
“Kymera's recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape. The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026. We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”
Next report
Date not yet announcedValuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Kymera Therapeutics report Q3 2026 earnings?
- Kymera Therapeutics (KYMR) reported Q3 2026 earnings on October 29, 2026 before market open.
- What were Kymera Therapeutics's Q3 2026 revenue and EPS?
- Kymera Therapeutics reported revenue of $1.4M and eps of $-1.32 for Q3 2026.
- Did Kymera Therapeutics beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $3.3M by $1.9M. EPS missed the consensus estimate of $-1.26 by $0.06.
- How did Kymera Therapeutics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 51.2% from $2.8M a year earlier and eps declined 46.7% from $-0.90.
- Where can I find Kymera Therapeutics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-436965) and the 10-Q periodic report (0001193125-26-436975) directly on SEC EDGAR. The filing index links above go to sec.gov.
